Developer docs
API playgroundTry for free, no card

Search company profiles

NeoPhore

Full company profile

uuid000237w

Namestring
NeoPhore
Legal namestring
NeoPhore Limited
Websiteurl
neophore.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

NeoPhore Limited is a UK-based, privately held immuno-oncology biotech founded in 2017 and headquartered in Cambridge. The company is developing small-molecule drugs that target the DNA mismatch repair (MMR) pathway as a mechanism to enhance cancer immunotherapy, positioning itself in the neoantigen immuno-oncology space via a small-molecule (rather than biologic or cell-therapy) modality. Its single core offering is a discovery-stage pipeline of MMR-pathway modulators, with a stated goal of delivering a lead clinical candidate by 2025; no product has reached clinical testing as of the source data.

The business model is pre-commercial: NeoPhore generates no revenue today and monetizes exclusively through equity financing and grant funding. It has raised approximately £31.1M (~$39.5M) in cumulative Series B funding (including a 2024 £9.6M / ~$12.2M extension) plus an Innovate UK grant, with Bristol Myers Squibb participating as a strategic pharma investor in the 2024 oversubscribed extension. Capital is deployed into medicinal-chemistry-led drug discovery with a lean 1-10 person organization.

The company operates with no distribution or commercial channels today, relying instead on scientific publications, investor relations, and conference participation for visibility. Its customer base upon commercialization will be oncology patients reached through future pharma partnerships or direct commercialization; no current pharma licensing, co-development, or royalty arrangements are disclosed.

Short descriptiontext

NeoPhore is a Cambridge, UK-based pre-revenue biotech developing small-molecule drugs that target the DNA mismatch repair pathway for cancer immunotherapy, with a lead candidate targeted for 2025 and funding from a syndicate including Bristol Myers Squibb.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLondon, United Kingdom
HQ citystring
London
HQ countrystring
United Kingdom
HQ regionstring
Europe
Markets served

Serves global market

Keyword5 values
cancer immunotherapy, small molecule drugs, DNA mismatch repair, immuno-oncology therapeutics, oncology drug discovery
Industry2 codes
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
Social media profiles1 record
Marketing channels1 record

Each record includes

Title, Type, Stage, Description, Source

Cost components3 values
Technology or R&D, Personnel, Operations
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

NeoPhore is a pre-clinical stage immuno-oncology company developing small molecule drugs that target the DNA mismatch repair (MMR) pathway to stimulate the immune system against cancer. The company's drug discovery pipeline focuses on neoantigen-generating therapeutics intended to enhance cancer immunotherapy responses, with a lead drug candidate targeted to enter clinical testing by 2025.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Lead drug candidate expected to enter clinical testing by 2025
Product overview1 text field

NeoPhore is a small molecule neoantigen immuno-oncology company developing a drug pipeline targeting the DNA mismatch repair (MMR) pathway for cancer immunotherapy. The company's single core offering is its small molecule drug discovery platform focused on MMR pathway modulation, with a lead drug candidate expected to enter clinical testing by 2025.

Product and service1 record
1Small Molecule MMR Pathway Drug Pipeline
CategoryImmuno-oncology therapeutics
Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Market position
Competitive moat3 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds6 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors11 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

NeoPhore

Oncology Therapeuticsneophore.com

NeoPhore is a Cambridge, UK-based pre-revenue biotech developing small-molecule drugs that target the DNA mismatch repair pathway for cancer immunotherapy, with a lead candidate targeted for 2025 and funding from a syndicate including Bristol Myers Squibb.

What NeoPhore does

NeoPhore Limited is a UK-based, privately held immuno-oncology biotech founded in 2017 and headquartered in Cambridge. The company is developing small-molecule drugs that target the DNA mismatch repair (MMR) pathway as a mechanism to enhance cancer immunotherapy, positioning itself in the neoantigen immuno-oncology space via a small-molecule (rather than biologic or cell-therapy) modality. Its single core offering is a discovery-stage pipeline of MMR-pathway modulators, with a stated goal of delivering a lead clinical candidate by 2025; no product has reached clinical testing as of the source data.

The business model is pre-commercial: NeoPhore generates no revenue today and monetizes exclusively through equity financing and grant funding. It has raised approximately £31.1M (~$39.5M) in cumulative Series B funding (including a 2024 £9.6M / ~$12.2M extension) plus an Innovate UK grant, with Bristol Myers Squibb participating as a strategic pharma investor in the 2024 oversubscribed extension. Capital is deployed into medicinal-chemistry-led drug discovery with a lean 1-10 person organization.

The company operates with no distribution or commercial channels today, relying instead on scientific publications, investor relations, and conference participation for visibility. Its customer base upon commercialization will be oncology patients reached through future pharma partnerships or direct commercialization; no current pharma licensing, co-development, or royalty arrangements are disclosed.

NeoPhore firmographics

Firmographics
Name
NeoPhore
Legal name
NeoPhore Limited
Website
https://neophore.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
NeoPhore is a Cambridge, UK-based pre-revenue biotech developing small-molecule drugs that target the DNA mismatch repair pathway for cancer immunotherapy, with a lead candidate targeted for 2025 and funding from a syndicate including Bristol Myers Squibb.
Ownership category
akta.pro rank

NeoPhore industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAANAK
Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Cancer immunotherapy
  • Small molecule drugs
  • DNA mismatch repair
  • Immuno-oncology therapeutics
  • Oncology drug discovery

Where NeoPhore is headquartered

Location

Headquarters

HQ city
London
HQ country
United Kingdom
HQ region
Europe

Markets served

NeoPhore business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations

Marketing channels1 record

NeoPhore product offering

Product offering

Core offering

NeoPhore is a pre-clinical stage immuno-oncology company developing small molecule drugs that target the DNA mismatch repair (MMR) pathway to stimulate the immune system against cancer. The company's drug discovery pipeline focuses on neoantigen-generating therapeutics intended to enhance cancer immunotherapy responses, with a lead drug candidate targeted to enter clinical testing by 2025.

Product overview

NeoPhore is a small molecule neoantigen immuno-oncology company developing a drug pipeline targeting the DNA mismatch repair (MMR) pathway for cancer immunotherapy. The company's single core offering is its small molecule drug discovery platform focused on MMR pathway modulation, with a lead drug candidate expected to enter clinical testing by 2025.

Differentiator

Problem solved

Functional benefit

Products and services

  • Small Molecule MMR Pathway Drug Pipeline

Quantifiable outcome

  • Lead drug candidate expected to enter clinical testing by 2025

Companies that use NeoPhore

Customer profile

Segments1 record

Ideal customer profiles1 record

NeoPhore technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

NeoPhore partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves5 records

Expansion highlights4 records

NeoPhore competitors and assessment

Company assessment

Market position

Competitive moat3 records

Key risks6 records

Key highlights6 records

Customer concentration

NeoPhore social profiles

Digital presence

NeoPhore financial estimates

Financial estimate

Revenue estimate

Valuation estimate

NeoPhore leadership team

Management profile

Number of profiles

Profiles3 records

NeoPhore funding detail

Funding detail

Funding overview

Funding rounds6 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

NeoPhore M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NeoPhore

What does NeoPhore do?

NeoPhore is a pre-clinical stage immuno-oncology company developing small molecule drugs that target the DNA mismatch repair (MMR) pathway to stimulate the immune system against cancer. The company's drug discovery pipeline focuses on neoantigen-generating therapeutics intended to enhance cancer immunotherapy responses, with a lead drug candidate targeted to enter clinical testing by 2025.

Is NeoPhore a public or private company?

NeoPhore is a private company. It is classified as venture growth investor backed and is currently operating.

When was NeoPhore founded?

NeoPhore was founded in 2017. It employs 11 to 50 people.

Where is NeoPhore based?

NeoPhore is headquartered in London, United Kingdom, in the Europe region.

Does NeoPhore have an API?

No public API is recorded for NeoPhore.

What industry is NeoPhore in?

NeoPhore's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAAANAK, Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies), with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 325414 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
FinSMEsNeoPhore Closes Series B Extension RoundNeoPhore, a Cambridge-based immuno-oncology company, closed a Series B extension funding round with an investment from Bristol Myers Squibb. The company plans to utilize the undisclosed funds to advance pre-clinical studies and target novel biology within the DNA mismatch repair pathway for cancer therapeutics. This strategic investment supports NeoPhore's goal of delivering a candidate drug by 2025.FinSMEsNeoPhore Raises Additional £9.6M in Series B Extension FinancingNeoPhore raised an additional £9.6M in Series B extension financing, bringing total funding to £31.1M. The round included existing investors and three new ones, with funds to advance its drug discovery pipeline. The company aims to deliver a candidate drug for its lead PMS2 program by early 2025.PR NewswireNeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipelineNeoPhore Limited announced a £9.6 million extension to its Series B financing round, bringing the total raised to £31.1 million with participation from existing investors and three new entities: NEVA SGR, LIFTT, and Simon Fiduciaria. The additional capital will be utilized to advance NeoPhore's lead oral program through early pre-clinical development for immuno-oncology therapeutics targeting the DNA mismatch repair pathway. This funding supports the company's goal of delivering a candidate drug for its PMS2 program by early 2025.NeophoreNeoPhore raises an additional £9.6m (USD $12.2m) Series B financing extension to further progress drug discovery pipelineNeoPhore Limited secured an additional £9.6 million in Series B financing, bringing the total raised to £31.1 million, with participation from existing investors and new backers NEVA SGR, LIFTT, and Simon Fiduciaria. The company intends to use these funds to advance its lead oral drug candidate through early pre-clinical development for immuno-oncology treatments.PR NewswireNeoPhore completes extension to Series B financing to further advance discovery pipelineNeoPhore Limited, a UK-based small molecule neoantigen immuno-oncology company, completed a £21.5 million (US $28.5 million) Series B financing including a £6 million (US $7.5 million) extension. The funding round was co-led by CRT Pioneer Fund, Claris Ventures, 2Invest, 3B Future Health Fund, and Astellas Venture Management. The company achieved all investment-related scientific milestones ahead of schedule in January 2022 and will use the proceeds to advance its drug pipeline toward IND-enabling studies in 2024.FinSMEsNeoPhore Closes £6M Extension to Series B; Round to £21.5MNeoPhore, a Cambridge-based immuno-oncology company, closed a £6 million extension to its Series B funding round, bringing the total raised to £21.5 million with participation from investors including Astellas Venture Management and CRT Pioneer Fund. The company plans to utilize these funds to advance its pipeline of small molecule therapies toward IND-enabling studies in 2024.PR NewswireNeoPhore completes extension to Series B financing to further advance discovery pipelineNeoPhore Limited has completed its Series B financing with a total value of £21.5 million, including a £6 million extension from existing investors. The company plans to use these funds to advance its pipeline of small molecule immuno-oncology drugs toward IND-enabling studies in 2024. This funding follows significant scientific milestones achieved ahead of schedule and expanded research collaborations.dlvr.itNeoPhore gains additional financing for discovery pipelineNeoPhore has completed a £21.5 million Series B financing round, which includes an additional £6 million extension, to advance its pipeline of small molecule neoantigen immuno-oncology therapies. The funding, provided by investors including Claris Ventures and Astellas Venture Management, will support the company as it prepares for IND-enabling studies in 2024.PharmiWeb.comNeoPhore completes extension to Series B financing to further advance discovery pipelineNeoPhore Limited has completed an extension to its Series B financing, securing a total of £21.5 million (US $28.5 million) from existing investors including CRT Pioneer Fund and Astellas Venture Management. The additional capital will be utilized to advance the company's pipeline of small molecule drugs targeting the DNA mismatch repair pathway toward IND-enabling studies in 2024.NeophoreNeoPhore completes extension to Series B financing to further advance discovery pipelineNeoPhore Limited has completed a £21.5 million Series B financing round, including a £6 million extension, to advance its immuno-oncology drug discovery pipeline. The funding will support the progression of its small molecule drugs targeting the DNA mismatch repair pathway toward IND-enabling studies in 2024.